489 related articles for article (PubMed ID: 35935962)
1. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
Mei S; Fan Z; Liu X; Zhao F; Huang Y; Wei L; Hu Y; Xie Y; Wang L; Ai B; Liang C; Xu F; Guo F
Front Immunol; 2022; 13():911164. PubMed ID: 35935962
[TBL] [Abstract][Full Text] [Related]
2. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.
Pérez P; Albericio G; Astorgano D; Flores S; Sánchez-Corzo C; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2023; 14():1264323. PubMed ID: 38155964
[TBL] [Abstract][Full Text] [Related]
3. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():845969. PubMed ID: 35371064
[TBL] [Abstract][Full Text] [Related]
4. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
[TBL] [Abstract][Full Text] [Related]
5. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
[TBL] [Abstract][Full Text] [Related]
7. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins.
Chen J; Xu W; Li L; Yi L; Jiang Y; Hao P; Xu Z; Zou W; Li P; Gao Z; Tian M; Jin N; Ren L; Li C
Front Cell Infect Microbiol; 2022; 12():967493. PubMed ID: 35923799
[TBL] [Abstract][Full Text] [Related]
9. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2021; 12():824728. PubMed ID: 35154086
[TBL] [Abstract][Full Text] [Related]
10. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
12. Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.
Kulkarni R; Chen WC; Lee Y; Kao CF; Hu SL; Ma HH; Jan JT; Liao CC; Liang JJ; Ko HY; Sun CP; Lin YS; Wang YC; Wei SC; Lin YL; Ma C; Chao YC; Chou YC; Chang W
PLoS One; 2021; 16(9):e0257191. PubMed ID: 34499677
[TBL] [Abstract][Full Text] [Related]
13. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
14. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
Eldi P; Cooper TH; Prow NA; Liu L; Heinemann GK; Zhang VJ; Trinidad AD; Guzman-Genuino RM; Wulff P; Hobbs LM; Diener KR; Hayball JD
Immunol Cell Biol; 2022 Apr; 100(4):250-266. PubMed ID: 35188985
[TBL] [Abstract][Full Text] [Related]
15. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
16. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.
Routhu NK; Gangadhara S; Lai L; Davis-Gardner ME; Floyd K; Shiferaw A; Bartsch YC; Fischinger S; Khoury G; Rahman SA; Stampfer SD; Schäfer A; Jean SM; Wallace C; Stammen RL; Wood J; Joyce C; Nagy T; Parsons MS; Gralinski L; Kozlowski PA; Alter G; Suthar MS; Amara RR
Sci Immunol; 2022 Jun; 7(72):eabo0226. PubMed ID: 35357886
[TBL] [Abstract][Full Text] [Related]
17. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
[TBL] [Abstract][Full Text] [Related]
18. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
19. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
[TBL] [Abstract][Full Text] [Related]
20. Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2.
Mooij P; García-Arriaza J; Pérez P; Lázaro-Frías A; Verstrepen BE; Böszörményi KP; Mortier D; Fagrouch Z; Kiemenyi-Kayere G; Niphuis H; Acar RF; Meijer L; Stammes MA; Kondova I; Verschoor EJ; GeurtsvanKessel CH; de Bruin E; Sikkema RS; Luczkowiak J; Delgado R; Montenegro D; Puentes E; Rodríguez E; Bogers WMJM; Koopman G; Esteban M
Front Immunol; 2022; 13():845887. PubMed ID: 35371043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]